25 completed, 6 recruiting, 3 terminated, 2 unknown. 38 Phase 1, 15 Phase 2.
Follow Diabetic Nephropathies: new trials by email Literature Review of Diabetic Nephropathies trials Research Report on Diabetic Nephropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial Umbilical Cord Mesenchymal Stem Cells - Diabetic Nephropathy Type 2 | Phase 1 / Phase 2 | Recruiting | PT. Prodia Stem Cell Indonesia | 10 | 2026-07-01 | 2026-02-09 |
| Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease MTX-439, Placebo - Healthy Adult Participants, Diabetic Kidney Disease | Phase 1 | Recruiting | Mediar Therapeutics | 88 | 2026-05-19 | 2026-06-29 |
| Human Umbilical Cord Mesenchymal Stem Cell Injection for Diabetic Nephropathy UC-MSCs, Placebo - Diabetic Nephropathy | Phase 1 | Recruiting | Tongji Hospital | 15 | 2026-03-25 | 2026-09-16 |
| Mesenchymal Stem Cells for Chronic Kidney Diseases 0.9% sodium chloride, MSCs - Kidney Disease, Chronic, Diabetic Kidney Disease (DKD) | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 32 | 2026-01-01 | 2025-12-24 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort AZD4248, Placebo - Chronic Kidney Disease | Phase 1 | Recruiting | AstraZeneca | 124 | 2025-06-09 | 2026-08-12 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients AP303 150μg, Placebo 150μg - Diabetic Kidney Disease | Phase 1 | Recruiting | Alebund Pharmaceuticals | 18 | 2025-02-27 | 2025-09-11 |
| Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease Dendritic cell immunotherapy - Diabetic Kidney Disease (DKD) | Phase 1 / Phase 2 | Active not recruiting | PT. JES Kasih Nusantara Sejahterah | 80 | 2024-05-01 | 2025-12-05 |
| A Study of Participants With Chronic Kidney Disease Previously Treated With REACT Renal Autologous Cell Therapy (REACT) - Diabetic Kidney Disease, CAKUT | Phase 1 | Terminated | Prokidney | 1 | 2023-07-11 | 2025-02-28 |
| MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution - Type 1 Diabetes, Diabetic Kidney Disease | Phase 1 | Recruiting | Kalie Tommerdahl | 60 | 2022-07-01 | 2025-06-13 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) CLBS201 - Chronic Kidney Diseases | Phase 1 | Completed | Lisata Therapeutics, Inc. | 6 | 2022-01-10 | 2024-10-09 |
| Stem Cell Therapy for Chronic Kidney Disease Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions - Chronic Kidney Diseases, Diabetes Mellitus, Type 2 | Phase 1 | Completed | LaTonya J. Hickson | 10 | 2021-10-07 | 2025-06-06 |
| Dosimetry of Tc-99m-Tilmanocept Tc-99m-Tilmanocept - Diabetic Kidney Disease | Phase 1 | Completed | University of California, San Diego | 57 | 2021-08-06 | 2026-07-14 |
| Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects HEC73077 tablets, HEC73077 placebo tablets - Diabetic Nephropathy | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 138 | 2021-05-24 | 2023-04-12 |
| First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes GFB-024, Placebo - Kidney Diseases, Diabetic Nephropathies | Phase 1 | Completed | Goldfinch Bio, Inc. | 39 | 2021-05-05 | 2022-03-28 |
| Use of Wharton Jelly in Diabetic Nephropathy Wharton Jelly Mesenchymal stem cells - Diabetic Nephropathies | Phase 1 / Phase 2 | Unknown | Sophia Al-Adwan | 20 | 2019-11-01 | 2019-07-24 |
| Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose - Diabetic Kidney Disease, Diabetic Nephropathies | Phase 1 | Terminated | Mayo Clinic | 2 | 2019-10-23 | 2025-08-17 |
| FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects GFB-887, Placebo - Healthy Volunteers | Phase 1 | Completed | Goldfinch Bio, Inc. | 70 | 2019-05-29 | 2020-06-02 |
| Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL - Diabetes Mellitus, Type 1, Nephropathy | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 50 | 2018-10-01 | 2022-04-20 |
| Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL, Vertical Sleeve Gastrectomy - Type 2 Diabetes Mellitus, Obesity | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 24 | 2018-10-01 | 2026-01-12 |
Showing 20 of 38. Sign in to see all of them.
Kidney Diseases (8) · Renal Insufficiency, Chronic (8) · Diabetes Mellitus (7) · Diabetes Mellitus, Type 2 (7) · Diabetes Mellitus, Type 1 (5) · Diabetes Complications (4) · Proteinuria (3) · Endocrine System Diseases (2) · Glomerulosclerosis, Focal Segmental (2) · Cakut (1) · Cardiovascular Diseases (1) · Disease Progression (1) · Glomerulonephritis (1) · Glomerulonephritis, IGA (1)
Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Male Urogenital Diseases (38) · Urogenital Diseases (38) · Urologic Diseases (37) · Endocrine System Diseases (36) · Diabetes Complications (34) · Diabetes Mellitus (31) · Kidney Diseases (30) · Glucose Metabolism Disorders (13) · Nutritional and Metabolic Diseases (13) · Metabolic Diseases (12) · Pathological Conditions, Signs and Symptoms (12) · Disease Attributes (9) · Pathologic Processes (9)
Iohexol (3) · p-Aminohippuric Acid (3) · 1-(5-hydroxyhexyl)-3,7-dimethylxanthine (1) · 2-(3-chlorophenylamino)phenylacetic acid (1) · Bariatric Surgery (1) · Calcium Carbonate (1) · Colchicine (1) · Eplerenone (1) · Injections (1) · Metformin (1) · PF-04634817 (1) · Sevelamer (1) · Sodium Chloride (1) · Soybean Proteins (1) · apararenone (1)
Boehringer Ingelheim (2) · Goldfinch Bio, Inc. (2) · Tanabe Pharma Corporation (2) · University of Colorado, Denver (2) · Alebund Pharmaceuticals (1) · Alexion Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Bayer (1) · Concert Pharmaceuticals (1) · Dong Wha Pharmaceutical Co. Ltd. (1) · Eli Lilly and Company (1) · Gilead Sciences (1) · Glycadia (1) · Icahn School of Medicine at Mount Sinai (1) · Kalie Tommerdahl (1)
United States (20) · China (3) · Germany (3) · Australia (2) · Indonesia (2) · Japan (2) · South Korea (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1)
Masaomi Nangaku, Professor (2) · Petter Bjornstad, MD (2) · Abdalla Awidi, MD (1) · Carl Hoh, MD (1) · Cheol-hee Lim, CR Manager (1) · Giuseppe Remuzzi, MD (1) · Gregory Tracey, MD (1) · Helen Vlassara, MD (1) · Hong Zhang (1) · Ingela Danielsson, MD, PhD, MBA (1) · Jeanelle Kam, MD (1)
PMID 27743903, PMID 30825073, PMID 32737116, PMID 35507146, PMID 36623423, PMID 37560967, PMID 37783947, PMID 38497241, PMID 39727944, PMID 39727950, PMID 39727989, PMID 39852146, PMID 40009460, PMID 40333016, PMID 41141513, PMID 41708511, PMID 41805697
2014 (1), 2015 (1), 2016 (1), 2017 (1), K23HL159292 (1), R01DK063017 (1)